Goldman Sachs Group Inc. Has $791,000 Position in CryoPort, Inc. $CYRX

Key Points

• Goldman Sachs reduced its stake in CryoPort, Inc. by 37.5%, now holding 0.26% of the company valued at approximately $791,000.
• CryoPort's stock experienced a decline of 3.2%, with a current price of $9.81 and a market cap of $491.19 million.
• Insiders have sold a total of 80,028 shares worth $661,252 in the last 90 days, indicating potential changes in executive confidence or strategy.

Goldman Sachs Group Inc. trimmed its position in CryoPort, Inc. (NASDAQ:CYRX - Free Report) by 37.5% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 130,145 shares of the company's stock after selling 77,969 shares during the quarter. Goldman Sachs Group Inc. owned 0.26% of CryoPort worth $791,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Acadian Asset Management LLC boosted its position in shares of CryoPort by 106.4% in the first quarter. Acadian Asset Management LLC now owns 479,695 shares of the company's stock valued at $2,911,000 after acquiring an additional 247,288 shares during the period. Readystate Asset Management LP increased its position in CryoPort by 91.6% during the first quarter. Readystate Asset Management LP now owns 500,344 shares of the company's stock worth $3,042,000 after acquiring an additional 239,153 shares during the period. AQR Capital Management LLC raised its stake in CryoPort by 285.5% in the 1st quarter. AQR Capital Management LLC now owns 262,596 shares of the company's stock worth $1,597,000 after purchasing an additional 194,482 shares in the last quarter. Trexquant Investment LP boosted its holdings in CryoPort by 57.7% in the 1st quarter. Trexquant Investment LP now owns 377,127 shares of the company's stock valued at $2,293,000 after purchasing an additional 137,989 shares during the period. Finally, Nuveen LLC bought a new stake in CryoPort in the 1st quarter valued at about $743,000. Institutional investors own 92.90% of the company's stock.

CryoPort Stock Down 3.2%

CryoPort stock opened at $9.81 on Wednesday. The firm has a market cap of $491.19 million, a price-to-earnings ratio of 7.38 and a beta of 1.62. CryoPort, Inc. has a 52-week low of $4.58 and a 52-week high of $10.46. The company has a debt-to-equity ratio of 0.39, a quick ratio of 15.47 and a current ratio of 16.24. The firm has a 50 day moving average price of $8.52 and a two-hundred day moving average price of $7.09.

CryoPort (NASDAQ:CYRX - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.09). CryoPort had a negative return on equity of 9.79% and a net margin of 37.21%.The firm had revenue of $45.45 million for the quarter, compared to analyst estimates of $41.74 million. CryoPort has set its FY 2025 guidance at EPS. Equities analysts predict that CryoPort, Inc. will post -0.99 EPS for the current year.

Insider Activity at CryoPort

In other CryoPort news, CFO Robert Stefanovich sold 9,300 shares of the stock in a transaction that occurred on Tuesday, August 19th. The stock was sold at an average price of $8.67, for a total transaction of $80,631.00. Following the transaction, the chief financial officer directly owned 207,213 shares in the company, valued at approximately $1,796,536.71. This represents a 4.30% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Robert J. Hariri sold 25,000 shares of the firm's stock in a transaction that occurred on Thursday, September 11th. The stock was sold at an average price of $9.71, for a total transaction of $242,750.00. Following the sale, the director directly owned 51,275 shares of the company's stock, valued at approximately $497,880.25. This trade represents a 32.78% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 80,028 shares of company stock worth $661,252 in the last 90 days. Corporate insiders own 10.10% of the company's stock.

Wall Street Analyst Weigh In

CYRX has been the topic of several recent research reports. BTIG Research raised their target price on shares of CryoPort from $10.00 to $15.00 and gave the stock a "buy" rating in a report on Thursday, September 18th. KeyCorp raised CryoPort from a "sector weight" rating to an "overweight" rating and set a $15.00 price target on the stock in a research report on Wednesday, August 6th. Leerink Partners raised CryoPort from a "market perform" rating to an "outperform" rating and set a $16.00 price objective for the company in a report on Wednesday, August 6th. Stephens initiated coverage on CryoPort in a research report on Tuesday, July 22nd. They set an "overweight" rating and a $13.00 target price for the company. Finally, Leerink Partnrs upgraded CryoPort from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has assigned a Hold rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Buy" and a consensus target price of $12.56.

CryoPort Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.